Abstract
Abemaciclib is the first CDK 4/6 inhibitor to show a significant clinical benefit when added to adjuvant endocrine therapy in patients with high-risk, node-positive, HR-positive, HER2-negative, early-stage breast cancer, according to findings from the phase III monarchE trial.
Publisher
Oxford University Press (OUP)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献